Circulation, Vol 82, 2142-2151, Copyright © 1990 by American Heart Association
MT Johnstone, T Andrews, JA Ware, MA Rudd, D George, M Weinstein and J Loscalzo
The mechanism by which treatment with thrombolytic agents causes bleeding
is not known. Recently, frequency of bleeding events has been shown to
correlate with bleeding time, particularly in individuals treated with
aspirin. We examined the effects of streptokinase (20,000- 60,000 IU/kg) on
bleeding time in 40 rabbits pretreated with aspirin, a model for
fibrinolytic therapy. We then tested the effects of 1-
desamino-8-D-arginine vasopressin (DDAVP) (0.3 microgram/kg), an agent
known to reduce bleeding time in a variety of bleeding disorders, in 20
rabbits and compared the results with those of a control group of rabbits
receiving normal saline placebo. Aspirin increased the bleeding time from a
baseline mean +/- SEM value of 119 +/- 15 to 191 +/- 34 seconds in the
control group and from 114 +/- 6 to 188 +/- 18 seconds in the experimental
group. The addition of streptokinase increased the bleeding time to 592 +/-
119 seconds in the control group and 810 +/- 114 seconds in the
experimental group (p = NS). Subsequent infusion of DDAVP decreased the
bleeding time in the experimental group to 302 +/- 29 seconds (p less than
0.01 versus streptokinase) compared with 572 +/- 79 seconds (p = NS versus
streptokinase) in the control animals given saline placebo. In a subset of
rabbits receiving aspirin and streptokinase (40,000-60,000 IU/kg), samples
were obtained for platelet aggregation (n = 16), von Willebrand factor
antigen concentration (n = 17), and von Willebrand factor multimer
distribution (n = 14). Maximal rates of ADP-induced platelet aggregation
were not affected by DDAVP infusion, nor was the plasma concentration of
von Willebrand factor antigen, quantified by an immunoradiometric assay,
significantly affected by DDAVP infusion. Furthermore, the von Willebrand
factor multimer ratio decreased with DDAVP administration. These findings
indicate that aspirin and streptokinase combined result in a marked
increase in bleeding time that can be reduced by DDAVP. This effect of
DDAVP is not accompanied by an increase in platelet aggregation response,
plasma von Willebrand factor antigen concentration, or von Willebrand
factor multimer ratio.
ARTICLES
Bleeding time prolongation with streptokinase and its reduction with 1- desamino-8-D-arginine vasopressin
Division of Cardiology, Brigham and Women's Hospital, Boston, MA 02115.
This article has been cited by other articles:
![]() |
A. Inbal, O. Gurevitz, I. Tamarin, R. Eskaraev, A. Chetrit, I. Novicov, M. Feldman, D. Varon, M. Eldar, and J. Loscalzo Unique Antiplatelet Effects of a Novel S-Nitrosoderivative of a Recombinant Fragment of von Willebrand Factor, AR545C: In Vitro and Ex Vivo Inhibition of Platelet Function Blood, September 1, 1999; 94(5): 1693 - 1700. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. M. Mannucci Desmopressin (DDAVP) in the Treatment of Bleeding Disorders: The First 20 Years Blood, October 1, 1997; 90(7): 2515 - 2521. [Full Text] [PDF] |
||||
![]() |
A. Bernat, P. Hoffmann, A. Dumas, C. S.-L. Gal, D. Raufaste, and J. M. Herbert V2 Receptor Antagonism of DDAVP-Induced Release of Hemostasis Factors in Conscious Dogs J. Pharmacol. Exp. Ther., August 1, 1997; 282(2): 597 - 602. [Abstract] [Full Text] |
||||
![]() |
J. A. Ware and D. D. Heistad Platelet-Endothelium Interactions N. Engl. J. Med., March 4, 1993; 328(9): 628 - 635. [Full Text] |
||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1990 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |